// App-Quantinova.ai

184 : Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study

Researchers

Presenter

  • Iain McInnes

Principal Investigators

  • Josef S Smolen

  • Tore K Kvien

  • Luminita Pricop

  • Todd Fox

  • Lawrence Rasouliyan

  • Steffen Jugl

  • Corine Gaillez

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

  • Biostatistics, RTI Health Solutions, Barcelona, Spain,

Locations

  • United Kingdom

  • Austria

  • Norway

  • United States

  • Switzerland

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved